Lidak Pharm. [LDAKA] Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA]

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: luis a. garcia who wrote (415)	8/16/1997 12:37:00 PM
From: John Zwiener	of 1115

The reduction in healing time is the KEY endpoint for the FDA in considering approval. Lidak Pharm. says they got statistically significant results for this endpoint. According to the CEO, Katz, they did a variety of analysis, some that showed much better stats, but they chose the worst case analysis to report. If they are being accurate (and so far they seem to have been so far) then THEY DID IT. Withholding the numbers is said to be at the request of BMS and Yamanuchi. The secondary endpoints (like pain, itching, tingling) are also of importance for claiming other effects of the drug and are probably as or more important to the patients. Apparently, these outbreaks are very painful and distracting. The results here were even better. Mutual funds are interested also and are asking questions. A biotech company with good phase 3 results on a drug with such a large potentual market is worth much more than 3 dollars (total market cap of just over 100 million).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next